Zahra Aboulfathiyar Mohammadyar completed her Doctor of Pharmacy (Pharm.D.) — a six-year integrated program recognised as equivalent to a Master’s degree in Europe and a doctoral degree in countries including the USA, Australia, Iran, India, Hungary, and several Arab nations — at the Faculty of Pharmacy, Eastern Mediterranean University, North Cyprus. She successfully passed the highly competitive Iranian National Pharm.D. Equivalency Examination, achieving outstanding scores, and her degree will be officially recognised in Iran as Doctor of Pharmacy (Pharm.D.) in June 2026. Zahra is currently a Ph.D. candidate in Pharmaceutical Sciences at CIU University, North Cyprus, focusing her research on green pharmaceutical technologies. Her Pharm.D. thesis, supervised by Dr. Anahita Fathi Azarbayjani, achieved a breakthrough 63.5-fold solubility enhancement of sulfasalazine — the highest reported for this drug using deep eutectic solvent systems. This work has been accepted as a poster at WCP2026, for which she was honoured to receive the WCP2026 Emerging Scientist Travel Grant. She is the author of several internationally published, peer-reviewed articles and has actively participated in numerous specialised workshops, including animal model studies, cell culture techniques, and advanced pharmaceutical analysis.

Dr. Abdulhakim Abubakar is a Senior Lecturer in the Department of Pharmacology and Therapeutics at Ahmadu Bello University (ABU) Zaria. He holds a B. Pharm. (2010), MSc. Pharmacology (2016), Pharm. D (2018) and a Ph.D. in Pharmacology (2021) from ABU Zaria and University of Benin, Nigeria. His research focuses on Ethnopharmacology, Endocrinology, Biochemical Pharmacology and Toxicology. Dr. Abubakar has authored or co-authored over 28 peer-reviewed publications in reputable national and international journals. He is a frequent presenter at major conferences, including the World Congress of Pharmacology and International Diabetes Federation meetings, and has received several competitive travel grants and a TETFund research grant in Nigeria. Beyond research, he is a dedicated educator, teaching many undergraduate and postgraduate courses and currently supervising several postgraduate students. He is also a reviewer for many local and international journals.

Dr. Abdulhakim Abubakar is a Senior Lecturer in the Department of Pharmacology and Therapeutics at Ahmadu Bello University (ABU) Zaria. He holds a B. Pharm. (2010), MSc. Pharmacology (2016), Pharm. D (2018) and a Ph.D. in Pharmacology (2021) from ABU Zaria and University of Benin, Nigeria. His research focuses on Ethnopharmacology, Endocrinology, Biochemical Pharmacology and Toxicology. Dr. Abubakar has authored or co-authored over 28 peer-reviewed publications in reputable national and international journals. He is a frequent presenter at major conferences, including the World Congress of Pharmacology and International Diabetes Federation meetings, and has received several competitive travel grants and a TETFund research grant in Nigeria. Beyond research, he is a dedicated educator, teaching many undergraduate and postgraduate courses and currently supervising several postgraduate students. He is also a reviewer for many local and international journals.

Dr. Osama H. Abusara is an Associate Professor of Pharmacology at the Department of Pharmacy at Al-Zaytoonah University of Jordan (ZUJ), Jordan. He has been working at ZUJ since 2017. Dr. Abusara obtained his Ph.D. degree in Pharmacy and Pharmaceutical Sciences from the University of Manchester, UK, in 2017 and his B.Sc. degree in Pharmacy from the University of Jordan, Jordan, in 2014. Dr. Abusara’s research interests include investigating novel compounds for cancer treatments, repurposing existing drugs for cancer treatment, molecular cancer, and peptide synthesis. He also collaborates with researchers of different pharmaceutical fields. Dr. Abusara has authored and co-authored more than 30 published papers in leading scientific journals. Dr. Abusara is a member of the Jordanian Pharmacists Association since 2014.

Dr. Nayef Abdulaziz Aldabaan is an Assistant Professor and the Head of the Department of Pharmacology at Najran University, Saudi Arabia. He earned his Ph.D. in Pharmacy with a specialization in Pharmacology from the University of Louisiana at Monroe, USA, where his research focused on breast cancer cell signaling and the anticancer effects of γ-tocotrienol in human triple-negative breast cancer cells. Dr. Aldabaan has extensive experience in experimental design and cancer biology research. He has held leadership roles including Head of the Academic Advising Unit at College of Pharmacy, Najran University. Dr. Aldabaan is an associate member of the American Association for Cancer Research (AACR) and has published around 28 research articles in high-impact journals.

I am Ibrahim Mu’azzamu Aliyu, Ph.D., a Senior Lecturer in Pharmacology and Therapeutics at Ahmadu Bello University, Nigeria. With over a decade of experience in teaching, research, and community engagement, I specialize in pharmacology, toxicology, public health, and precision medicine. I have published more than 20 impact peer-reviewed articles and presented extensively at international conferences. My research focuses on respiratory pharmacology, ethnobotany, and drug safety, with ongoing projects on inflammatory and anti-cancer activities. A dedicated educator, I have developed curricula and mentored numerous postgraduate students. I am also actively involved in community health outreach and policy advocacy, fostering multidisciplinary collaborations across Nigeria and globally. Recognized for my leadership and innovation, I am committed to advancing pharmacological sciences and improving health outcomes through research, education, and community service.

Pervej Alom Barbhuiya is a pharmaceutical researcher with over two years of hands-on research experience in experimental pharmacology, currently serving as a Project Research Scientist-I (Non-Medical) under the Indian Council of Medical Research (ICMR) sanctioned project at Assam down town University, Guwahati. He is presently pursuing a Ph.D. with a strong research focus on metabolic syndrome, obesity, MASLD, diabetes, and associated co-morbidities. Academically, he completed his M. Pharm (Pharmacology) in 2022 and B. Pharm in 2020 from Assam down town University. His research credentials are further strengthened by prestigious fellowships, including ICMR Project Research Scientist-I and multiple Junior Research Fellowships, along with national scholarships awarded by the Ministry of Human Resource Development (MHRD). He has received several accolades for best oral and poster presentations at national and international conferences. He has contributed significantly to scientific literature, with 27 publications in Scopus and Web of Science indexed journals, achieving a cumulative impact factor of 80.5. In addition, he has actively participated in more than 60 scientific conferences, seminars, and workshops, and has played key roles in organizing academic events. Overall, Mr. Barbhuiya is a motivated and disciplined researcher with strong experimental skills, publication experience, and the ability to execute independent and collaborative research projects efficiently while adhering to timelines and scientific rigor.

Zehua Wang, also known as Zack Wang, is a PhD candidate in Pharmacology and Clinical Pharmacology at the University of Auckland, New Zealand, supervised by Associate Professor Jacqueline Hannam. His doctoral research focuses on model-informed dosing, Bayesian target concentration intervention, clinical trial simulation, pharmacometric methods, and pharmacoeconomic evaluation, with the aim of making high-risk medicines safer, more effective, and more sustainable in everyday clinical care. His current work investigates AUC-guided vancomycin dosing, using simulation frameworks to compare alternative dosing and monitoring strategies and evaluate sampling, ward-based treatment execution, target attainment, and economic implications. This work is driven by a commitment to bringing model-based dosing from the modelling bench to the bedside, especially for patients whose dosing needs are not well captured by standard assumptions, including Pacific and Māori peoples, older adults, children, and patients with obesity or impaired renal function.

Dr. Narumol Bhummaphan is a lecturer at the College of Public Health Sciences, Chulalongkorn University, Bangkok, Thailand. She holds a Ph.D. in Biomedical Sciences and brings three years of postdoctoral experience in molecular biology, alongside three years of lecturing in public health sciences. Dr. Bhummaphan is committed to advancing her academic and professional development and is eager to leverage fellowship opportunities to further her career.

Dr. Sohini Chakraborty is an assistant professor at REVA University, Bengaluru, and a PhD graduate of VIT, Vellore. Her research integrates bioinformatics, structural biology, and network pharmacology to advance the understanding of cancer, particularly breast cancer metastasis. She has received several prestigious accolades, including the DST International Travel Grant and multiple Best Oral and Best Poster Presentation awards, and serves as a Regional Ambassador of the Breast Cancer Hub (USA).

Chang, Jang-Yang, MD is a Chair Professor at the College of Medicine, Taipei Medical University, and Director of the TMU Research Center of Cancer Translational Medicine. He earned his medical degree from the National Defense Medical Center, Taipei, Taiwan. Dr. Chang has held several prominent positions, including Chair Professor and Superintendent of Taipei Cancer Center at Taipei Medical University; Distinguished Investigator and Director of the Institute of Biotechnology and Pharmaceutical Research at the National Health Research Institutes, Taiwan; Executive Vice President of National Cheng Kung University, Taiwan; Distinguished Professor and Dean of the College of Medicine at National Cheng Kung University; and Distinguished Professor and Director of the National Institute of Cancer Research, NHRI, Taiwan. He is certified by the Boards of Internal Medicine, Hematology, and Medical Oncology in Taiwan. His major research areas include anticancer drug clinical trials, anticancer drug development, and mechanism studies.

I am a passionate researcher in bone biology and molecular pharmacology, specializing in osteoporosis and the regulation of connexin 43 channels. My work at Jamia Hamdard and DIPAS, DRDO, centers on pioneering therapeutic approaches for osteoporosis by investigating osteoblast and osteoclast signaling pathways. I have developed expertise in both in vitro and in vivo experimental models, utilizing advanced techniques such as micro-CT, western blotting and molecular assays to examine the protective effects of Cx43 activators on bone. As the first author of a WCP conference abstract and with publications in reputed journals, I am dedicated to bridging the gap between fundamental research and clinical application. My academic journey includes top national entrance ranks (UPSEE, GPAT, NIPER) and active participation in scientific symposia. I was recognized with the Young Investigator Award at IPSCON 2025 in Chandigarh, acknowledging my contributions to the field.

Wan Suxin, female, born in 1989, graduated from Chongqing Medical University and serves as a clinical pharmacist at the Affiliated Three Gorges Hospital of Chongqing University. In 2021, she obtained the qualification as a clinical pharmacist specializing in endocrinology, and in 2024, she was certified as a clinical pharmacist instructor specializing in endocrinology. In the same year, she also received training to become a resident nursing supervisor for pharmacist positions.

PhD in Medicine, Member of the Respiratory and Comorbidities Branch of Chongqing Gerontology and Geriatrics Society. With over 10 years of clinical experience, has published more than 10 academic papers including those indexed in SCI journals, and has led and completed one municipal-level and one hospital-level research project each. Specializes in chemotherapy, molecular targeted therapy, anti-angiogenic therapy, and immunotherapy for common malignant tumors such as lung cancer and colorectal cancer.

Dr. Chen is an Assistant Research Fellow at the Agricultural Biotechnology Research Center, Academia Sinica. After starting her career as a pharmacist, she earned her Ph.D. from the Institute of Pharmacology at National Yang Ming Chiao Tung University. Before joining Academia Sinica, she was a research scientist at the Immunotherapy Research Center at Houston Methodist Research Institute. Drawing on her interdisciplinary expertise in pharmacy, pharmacology, and immunology, Dr. Chen’s research aims to connect basic scientific discovery with translational applications. Her primary focus is on developing new immunotherapies and natural product-based therapeutics. Her team investigates the biology of pathological myeloid cells—specifically how they interact with other cells in the tumor microenvironment and their role in subsequent immune responses. A significant area of her work involves studying these myeloid cells in the context of persistent inflammation, which is common in conditions like cancer and aging. Furthermore, Dr. Chen has identified several medicinal plant-derived products as potential myeloid-targeted phyto-medicines, offering promising directions for new drug development and immunomodulatory and nutritional therapies.

Dr. Yih-Fung Chen is an Associate Professor at the Graduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical University, Taiwan. She received her Ph.D. in Basic Medical Sciences from National Cheng Kung University (2010) and conducted visiting research at the University of Oxford (2008-2009). Dr. Chen's research focuses on three key areas: (1) discovering skin barrier protectants targeting antioxidant defense mechanisms and cellular senescence, with expertise in anti-aging strategies against UV-induced photodamage, anti-melanogenic compound development, and particulate matter-induced skin dysfunction; (2) exploring neuroprotective agents against chemotherapy-induced neurotoxicity; and (3) developing cancer therapeutics targeting intracellular calcium homeostasis and cytoskeletal dynamics. Her work integrates cellular imaging platforms with in vivo models to identify novel therapeutics derived from natural products. With over 50 peer-reviewed publications (h-index: 23), Dr. Chen has made significant contributions to the field of natural product pharmacology. Her recent work on dermal protection conferred by activation of the Nrf2 and AhR pathways (Toxicol Appl Pharmacol. 2025;505:117559; J Ethnopharmacol. 2026;360:121168), cellular senescence modeling in UV-irradiated skin cells (Poster 970, WCP2026), and anti-melanogenic natural compounds (Poster 968, WCP2026) demonstrates innovative approaches to skin health and anti-aging research.

Yen-Chang Chen is a PhD student at the Institute of Translational Medicine and New Drug Development, China Medical University (Taiwan). His research focuses on cancer progression, natural drug investigation, and drug repurposing, with particular emphasis on breast cancer and glioblastoma. He is especially interested in the interactions between tumor cells and immune cells. He has published several research articles related to cancer therapy and inflammatory diseases and actively presents his work at national and international conferences. His research aims to provide scientific evidence supporting the therapeutic potential in cancer treatment.

Dr. Yih-Fung Chen is an Associate Professor at the Graduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical University, Taiwan. She received her Ph.D. in Basic Medical Sciences from National Cheng Kung University (2010) and conducted visiting research at the University of Oxford (2008-2009). Dr. Chen's research focuses on three key areas: (1) discovering skin barrier protectants targeting antioxidant defense mechanisms and cellular senescence, with expertise in anti-aging strategies against UV-induced photodamage, anti-melanogenic compound development, and particulate matter-induced skin dysfunction; (2) exploring neuroprotective agents against chemotherapy-induced neurotoxicity; and (3) developing cancer therapeutics targeting intracellular calcium homeostasis and cytoskeletal dynamics. Her work integrates cellular imaging platforms with in vivo models to identify novel therapeutics derived from natural products. With over 50 peer-reviewed publications (h-index: 23), Dr. Chen has made significant contributions to the field of natural product pharmacology. Her recent work on dermal protection conferred by activation of the Nrf2 and AhR pathways (Toxicol Appl Pharmacol. 2025;505:117559; J Ethnopharmacol. 2026;360:121168), cellular senescence modeling in UV-irradiated skin cells (Poster 970, WCP2026), and anti-melanogenic natural compounds (Poster 968, WCP2026) demonstrates innovative approaches to skin health and anti-aging research.

Jian-Guo Chen received M.D. from Hubei University of Science and Technology, China, in 1985 and M.sci. from Tongji Medical University, China, in 1990. He obtained Ph. D from The University of Heidelberg, Germany, in 1998. He worked as a lecturer at Tongji Medical University, China, from 1990 to 1995, as a visiting scholar at The University of Kaiserslautern, Germany, from 1995 to 1996. He obtained postdoctoral training at The University of Iowa, USA, from 1998-2001, and since then, he has worked at Huazhong University of Science and Technology until now, served successively as a professor and The Chair of the Department of Pharmacology, The Director of the Office for Research and Development, Assistant President and Vice-President. He is a winner of the National Science Fund for Distinguished Young Scholars of China, Distinguished Professor of Yangtze Program of Ministry of Education of China, Chief Scientist of the Innovative Group of the National Natural Science Foundation of China, The Principal Scientist of National 973-Project and China Brain Project. His lab focuses on the pathophysiology for mood disorders and drug intervention, especially depression and anxiety. He has published more than 200 papers on peer-reviewed journals such as Nature Neuroscience, Cell Metabolism, Nature Metabolism, Nature Communcations, Biological Psychiatry, Molecular Psychiatry and British Journal of Pharmacology et al.

Miss Tzu-Peng Cheng, a licensed Medical Technologist, earned her Master’s degree in 2024 and is currently pursuing a Ph.D. at the Graduate Institute of Biomedical Sciences, Chang Gung University, Taiwan (R.O.C.). She specializes in neutrophil-driven inflammatory disorders, with a focus on acute lung injury, acute respiratory distress syndrome, and neutrophilic asthma. Through first-author publications and international conference presentations, she contributes to advancing pharmacological strategies that target neutrophil-mediated inflammation, bridging fundamental research with translational therapeutic approaches.

With 20 years of experience in dialysis nursing, the current nurse-in-chief possesses solid specialized theoretical knowledge and extensive clinical expertise. She demonstrates proficiency in various blood purification procedures and the observation and management of complications, with particular expertise in maintaining vascular access and providing patient health education. She is capable of delivering professional, safe, and compassionate nursing care to patients.

Shruti Chindam is a PhD research scholar under the guidance of Dr. Urmila Aswar in the Department of Pharmacology at Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be University), Pune, India. Her research focuses on liver and brain health, particularly Ayurvedic interventions for hepatic encephalopathy. She possesses expertise in network pharmacology, in vitro assays, and in vivo models, including bile duct ligation surgery in rats. She has presented her work at National and International conferences and authored one book chapter, a review article, and a research publication. Complementing her academic pursuits, she brings four years of corporate experience to her scientific endeavors.

Professor Bo-Hyun Choi is a pharmacologist and cancer biologist at the Department of Pharmacology, School of Medicine, Daegu Catholic University, Republic of Korea. She earned her B.S., M.S., and Ph.D. degrees in Pharmacy, specializing in pharmacology. Her research focuses on metabolic vulnerabilities in cancer, with particular emphasis on amino acid metabolism, redox homeostasis, and ferroptosis resistance. In the field of gerontology, she is dedicated to establishing cellular aging models to evaluate the anti-aging effects of novel small molecules. By integrating metabolomics and functional models, her work aims to identify reactive metabolite-based therapeutic strategies to overcome age-related diseases, metastasis, and treatment resistance.

Wei-Chung Chiou is a Postdoctoral Research Fellow at National Yang Ming Chiao Tung University (NYCU), Taiwan, specializing in molecular pharmacology and drug discovery. He received his Ph.D. in Biotechnology and Laboratory Science in Medicine from NYCU in 2025. His research focuses on the pharmacological mechanisms of small molecules in treating pulmonary fibrosis and metabolic disorders. His work elucidates molecular targets and offers evidence-based insights into the therapeutic potential of bioactive compounds.

Cara de Moura-Cunningham is a pharmacologist who has recently completed her MSc in Pharmacology at the University of Pretoria. Her preclinical research focused on factors influencing the uptake of doxorubicin in BT-20 triple-negative breast cancer spheroids, with an emphasis on advanced cell culture models and cell-based assays. She holds a BSc in Biochemistry and a BSc Honours degree in Pharmacology, both awarded cum laude. Her research interests include translational pharmacology, drug delivery, and improving the predictive value of in vitro preclinical models.

Shuqi Dong is a PhD candidate in the Drug Discovery Biology theme, Monash Institute of Pharmaceutical Sciences. Her project investigates compartmentalised oxytocin receptor signalling with a focus on receptor trafficking, spatiotemporal signalling and functional outcomes in cancer-relevant systems. Her work integrates advanced compartmentalised biosensor approaches with structural and mechanistic studies to understand how G protein-coupled receptor (GPCR) signalling location influences physiology and disease.

Yuan Zhou is an MS student in Neuroscience at Johns Hopkins University. Her research centers on neurodegenerative diseases, with a focus on glymphatic and meningeal lymphatic dysfunction, astrocytic metabolism, and neurovascular remodeling. She integrates advanced imaging, molecular techniques, and machine learning–based behavioral analysis to investigate mechanisms underlying disease progression. Yuan has co-authored peer-reviewed publications in neurodegeneration and neuro-oncology and has presented her work at international conferences.

The Pharmacy Department is an important clinical support department of the hospital, mainly responsible for the preparation, allocation, management and rational use of drugs. It undertakes the drug supply for inpatients and outpatients, and provides professional pharmaceutical care and drug consultation services.

I am a postdoctoral researcher at the University of Helsinki, Faculty of Medicine, specializing in cellular immunotherapy. My work has focused on developing novel solid tumor‑targeting CAR T cell constructs to overcome challenges in solid tumor therapy, with key findings on tonic signaling, persistence, and metastasis prevention. Building on this foundation, I am now pioneering CAR‑NK approaches for cardiac fibrosis, aiming to translate immunotherapy principles into regenerative medicine and fibrotic disease treatment.

Charles Okechukwu Esimone was born in Tiko, Cameroon. He graduated from St. Joseph’s College Sasse, Cameroon and with B. Pharm, M. Pharm and PhD from the University of Nigeria. He is Professor of Biopharmaceutics and Pharmaceutical Microbiology in the Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University and the Pioneer Dean of the Faculty. He is the immediate past Vice-Chancellor, Nnamdi Azikiwe University, Awka and currently a visiting Professor at Olivia University, Bujumbura Burundi. He is also the Prochancellor of European University of Nigeria (Abuja). He has well over 400 publications and was recently listed as the 18th Most Published Scholar in Nigeria. He was awarded the Honorary Professor of the Academic Union, Oxford University (AUO) for his outstanding professional achievements in Pharmaceutical Research and Innovation. He has pioneered research in the use of recombinant viral vectors as surrogates for high through-put antiviral screening studies and on the use of indigenous medicinal plants as immunomodulators, vaccine adjuvants and anti-infectives. He speaks English, French and German. He is a recipient of several awards which include the Alexander von Humboldt Fellowship to Germany (2003-2005), Visiting Scientist to the University of Pittsburgh, USA (2007-2008), the ANDI Bright Contest Award for the Best African Innovative Researcher, South Africa (2009), Young Scientist representing Nigeria at the “Summer davos” Annual Meeting of New Champions, Tianjin, China (2010) and the CV Raman Senior Fellowship, India (2013). He is a member of the Governing Council of the Pharmacists Council of Nigeria, the Nnamdi Azikiwe University and the Nanomedicine Society of Nigeria. He is a Fellow of the Nigerian Academy of Science, Fellow of the Pharmaceutical Society of Nigeria and Fellow of the Nigerian Academy of Pharmacy.

Charles Okechukwu Esimone was born in Tiko, Cameroon. He graduated from St. Joseph’s College Sasse, Cameroon and with B. Pharm, M. Pharm and PhD from the University of Nigeria. He is Professor of Biopharmaceutics and Pharmaceutical Microbiology in the Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University and the Pioneer Dean of the Faculty. He is the immediate past Vice-Chancellor, Nnamdi Azikiwe University, Awka and currently a visiting Professor at Olivia University, Bujumbura Burundi. He is also the Prochancellor of European University of Nigeria (Abuja). He has well over 400 publications and was recently listed as the 18th Most Published Scholar in Nigeria. He was awarded the Honorary Professor of the Academic Union, Oxford University (AUO) for his outstanding professional achievements in Pharmaceutical Research and Innovation. He has pioneered research in the use of recombinant viral vectors as surrogates for high through-put antiviral screening studies and on the use of indigenous medicinal plants as immunomodulators, vaccine adjuvants and anti-infectives. He speaks English, French and German. He is a recipient of several awards which include the Alexander von Humboldt Fellowship to Germany (2003-2005), Visiting Scientist to the University of Pittsburgh, USA (2007-2008), the ANDI Bright Contest Award for the Best African Innovative Researcher, South Africa (2009), Young Scientist representing Nigeria at the “Summer davos” Annual Meeting of New Champions, Tianjin, China (2010) and the CV Raman Senior Fellowship, India (2013). He is a member of the Governing Council of the Pharmacists Council of Nigeria, the Nnamdi Azikiwe University and the Nanomedicine Society of Nigeria. He is a Fellow of the Nigerian Academy of Science, Fellow of the Pharmaceutical Society of Nigeria and Fellow of the Nigerian Academy of Pharmacy.

Dr. Ogechukwu Ebere Ezim is a distinguished Lecturer in the Department of Biochemistry, University of Port Harcourt, Nigeria. With a strong foundation in Nutrition and Food Biochemistry, she holds a Ph.D. and M.Sc. from the University of Nigeria, Nsukka, and a B.Sc. from Madonna University, Nigeria. Dr. Ezim has built an impressive academic career spanning over a decade, rising through the ranks from Assistant Lecturer to Senior Lecturer. She is widely recognized for her contributions to reproductive biology, molecular toxicology, nutrition, and environmental biochemistry. Her research outputs include over 40 peer-reviewed journal articles and three book chapters, with ongoing doctoral supervision and mentorship of postgraduate and undergraduate students. She is a fellow of the African Science Leadership Programme (ASLP) and a recipient of several prestigious grants. She is a member of the Nigerian Society of Biochemistry and Molecular Biology and the Nutrition Society of Nigeria.

Ko Fujimori is a Professor in the Faculty of Pharmacy at Osaka Medical and Pharmaceutical University, Japan, with expertise in pharmaceutical sciences and research in drug development and pharmacology.

Ashleigh is a PhD candidate in the Cardiac G Protein-Coupled Receptor Laboratory led by Associate Professor Lauren May, at the Monash Institute of Pharmaceutical Sciences. He completed his Bachelor of Pharmaceutical Science Advanced (Honours) at Monash University, where his research explored the effects of positive allosteric modulators on adenosine A1 receptor (A1R) internalisation using confocal microscopy. His PhD research expands on this work by investigating the spatiotemporal dynamics, regulation, and signalling of the A1R in immortalised mammalian cells and iPSC derived neurons, employing a variety of techniques, including BRET based assays, confocal microscopy, and super resolution imaging.

I obtained a Bachelor of Science in Chemistry from Kabul University in 2016. Following graduation, I was appointed as a Lecturer in Biochemistry at Melat Medical Institute. In 2019, I commenced a Master of Science in Clinical Biochemistry in India, which I completed in 2021. Since 2021, I have been pursuing a Doctor of Philosophy (Ph.D.) in the Department of Biotechnology at Punjabi University, Patiala, India. My doctoral research focuses on the phenolic characterization of Silybum marianum utilizing bio-analytical techniques and the in vitro investigation of its hepatoprotective properties. I presented a paper entitled “Ethnopharmacology of Silybum marianum and its Phytoconstituents” at the National Conference on Empowering Humanity: Science, Technology, and Healthcare for All, November 6–8, 2025. I am eager to attend and present orally at this conference to share my research findings, as they directly align with the focus of my Ph.D. program. Best Regards, Mohammad Asif Gawhari,

Muhammad Ilham Gibran is a Master’s and doctoral-track student at Universitas Gadjah Mada, Indonesia, specializing in Biomedical Sciences (Pharmacology), with a Bachelor’s degree in Nutrition and a background in public health. His research focuses on the translational pharmacology of herbal and natural products, particularly galactagogues for maternal and child health. He has experience in systematic reviews, network pharmacology, and molecular docking. His doctoral research currently involves in vivo pharmacodynamic evaluation of a polyherbal formula containing Sauropus androgynus, Moringa oleifera, and Curcuma xanthorrhiza.

David Gloriam is a Professor in Computational Receptor Biology at the University of Copenhagen. His research focuses on G protein-coupled receptors (GPCRs) and their signal transducers. His group develops the online databases GPCRdb, GproteinDb, ArrestinDb and Biased Signaling Atlas serving as data and tool hubs for the global research community. Over the years, he has developed and applied data science approaches to uncover e.g., activation mechanisms, physiological peptide hormones and trends in GPCR drug discovery. Furthermore, through computational drug design he has identified tool compounds and lead drugs, and developed methods for small molecule and peptide design. Gloriam got his PhD from Uppsala University identifying novel human GPCRs referred to as “orphan” receptors due to their unknown physiological ligands and functions. In two postdocs in the UK at EMBL-EBI and GlaxoSmithKline, he conducted bioinformatics and computational drug design, respectively. He later joined the University of Copenhagen where he established his own group in 2013. He is a member of the nomenclature committee of the International Union of Pharmacology (NC-IUPHAR) contributing to the naming and guidelines for drugs and targets. He has been awarded major group leadership grants from the ERC, Lundbeck Foundation and Novo Nordisk Foundation, and a research prize within big data from the Royal Danish Academy of Sciences and Letters.

Karina Goluba is a PhD candidate, pharmacist, and researcher at the Faculty of medicine and life sciences and Department of Pharmaceutical sciences, University of Latvia. Her work focuses on the development of advanced in vitro cancer models, including 2D and 3D systems such as spheroids and organoids, as well as induced pluripotent stem cell (iPSC)-derived models. She also develops tumour models on organ-on-a-chip platforms to investigate drug response and evaluate novel therapeutic strategies.

Thomas Griffiths is a pharmacist and PhD candidate in the Molecular Toxicology laboratory in the School of Health and Clinical Sciences at the University of Western Australia. Thomas' research focusses on characterising "joint toxicity" whereby several related toxicants cause enhanced damage to biomolecules. His current research seeks to understand joint toxicity of mixtures of biogenic carbonyl compounds towards proteins and identify chemical features that predict protective efficacy of anti-carbonyl drugs. Thomas hopes to identify strategies to mitigate molecular toxicities that can aid drug discovery efforts in this area.

Debojyoti Halder is a Joint ASCRIN Ph.D. research scholar at the Department of Pharmacy, BITS-Pilani Hyderabad Campus and La Trobe University, Bundoora, Melbourne specializing in drug discovery for neurocognitive disorder and cancer treat- ment with histone deacetylase (HDAC) as a target enzyme under the guidance of Prof. Balaram Ghosh and Prof. Thiruma V. Arumugam. He was also an assistant professor at the School of Pharmaceutical Technology, Adamas University, Kolkata. His research focuses on computational drug discovery, molecular modeling with expertise in structure-based and ligand-based drug design, synthesis of designed molecules, in vitro biological studies, and in vivo pharmacokinetic analysis in neuroscience drug discovery. Debojyoti has strong experience in computational and synthetic medicinal chemistry and in structure–activity relationship (SAR) studies.

Junho Lee, Ph.D., is a postdoctoral researcher in the department of pharmacology, Avison Biomedical Research Center (ABMRC), Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea. His research focuses on virology, specifically investigating virus-induced cell membrane fusion and developing novel inhibitors targeting host factors like ANO6. He is a co-presenter for the abstract titled "Novel ANO6 inhibitors that block virus-induced cell membrane fusion" at this congress.

The author is a doctoral candidate in Traditional Chinese Medicine at Nanjing University of Chinese Medicine, specializing in the field of antiviral Chinese medicine.

Dr. Ryusuke Hosoda is an Assistant Professor in the Department of Pharmacology at Sapporo Medical University, Japan. His research investigates the molecular mechanisms of sarcopenia and aging, focusing on mitochondrial protein acetylation and SIRT1 signaling in skeletal muscle. He aims to develop therapeutic strategies for muscle decline, exploring the pharmacological potential of natural compounds to restore mitochondrial function.

Dr. Tsung-I Hsu was born in Taichung, Taiwan, and is an Associate Professor in the Ph.D. Program of Medical Neuroscience at Taipei Medical University. He obtained his PhD from the Institute of Basic Medical Sciences at National Cheng Kung University (2007–2012) and completed his Master of Science in Physiology at the same institution (2004–2007). Following his doctoral training, Dr. Hsu undertook postdoctoral research at the Center of Infectious Disease and Signal Transduction, National Cheng Kung University. He subsequently held several research leadership roles at Taipei Medical University, including Project-Directed Research Fellow in the Ph.D. Program for Neural Regenerative Medicine and Assistant Principal Investigator at both the Center for Neural Trauma and Regeneration and the Research Center of Neuroscience. Dr. Hsu joined the Ph.D. Program of Medical Neuroscience at Taipei Medical University as an Assistant Professor in 2019 and was promoted to Associate Professor in 2022. His academic career reflects a strong commitment to neuroscience research, neural regeneration, and medical education.

Dr Laura Humphrys was recruited to the Monash Institute of Pharmaceutical Sciences in 2023 for her current position as a Postdoctoral Research Fellow to investigate metabolic receptor pharmacology in the lab of Prof Denise Wootten and Prof Patrick Sexton. Laura earned her integrated master's degree in neuroscience from the University of Nottingham, UK (1 year with the University of Melbourne, Australia) in 2015. She was then awarded and AJ Clark Studentship from the British Pharmacological Society in 2015 to perform her postgraduate research on light-activated cell membrane receptors. Following her PhD, Laura was recruited to the University of Regensburg, Germany in 2019 as a cell-based postdoctoral scientist in a peptide-based medicinal chemistry lab. Her research interests include visualisation and genetic modification of cell receptors in physiologically relevant cells.

Distinguished Research Professor, School of Medicine, Fu Jen Catholic University; Director, Department of Community Medicine and Long-Term Care, Fu Jen Catholic University Hospital, Taiwan Prof. Hung received his bachelor’s degree from Kaohsiung Medical University and his master’s and doctoral degrees from the Institute of Pharmacology, National Taiwan University. He has been a full-time faculty member at the School of Medicine, Fu Jen Catholic University (FJCU), since 2002. He has held several major academic leadership positions at FJCU, including Director of the Interdisciplinary Master’s Program in Long-Term Care (2015–2024), Director of the PhD Program in Pharmaceutical Biotechnology (2017–2025), Associate Dean of the College of Medicine, and Dean of Research and Development. Prof. Hung has received numerous honors for excellence in teaching, research, and service from both the Ministry of Education, Taiwan, and FJCU. He was recognized as a World’s Top 2% Scientist by Stanford University and Elsevier (2020–2024). His research focuses on the pharmacodynamics of drugs and natural products, as well as the prevention and treatment of aging-related disorders, including retinopathy and cardiovascular diseases. He is dedicated to advancing research and education that promote healthy aging in an aging society.

Jan-Jong Hung (Peter) is a Professor at National Cheng Kung University (NCKU) in Tainan, Taiwan. His laboratory has focused on lung cancer for more than twenty years. The group is dedicated to studying the genetic mutations underlying lung cancer, with research primarily targeting two key areas: understanding genome instability and the DNA repair mechanisms that prevent lung cancer formation, and uncovering the mechanisms responsible for lung cancer development while developing innovative treatments. Significant progress has been made through the application of molecular biology, structural biology, bioinformatics, and the analysis of both Eastern and Western lung cancer animal models and clinical specimens. Building on these successes, the laboratory is committed to further enhancing strategies for lung cancer prevention and treatment, aiming to make a meaningful contribution to the field.

Dr. Tsong-Long Hwang is the Vice President and a Distinguished Professor at Chang Gung University of Science and Technology. He also holds several prominent roles, including President of the Society for Free Radical Research in Taiwan, President of the Taiwan Association for Traditional and Complementary Medicine, and Honorary President of the Society of Chinese Natural Medicine in Taiwan. He holds multiple joint appointments, serving as a Jointly Appointed Professor at Chang Gung University, Ming Chi University of Technology, and National Yang Ming Chiao Tung University. He is also a Jointly Appointed Research Fellow at Chang Gung Memorial Hospital. Additionally, he serves as Field Chief Editor for the journal "Frontiers in Natural Products." Dr. Hwang earned his Ph.D. in Pharmacology from National Taiwan University in 2000. His research laboratory uses pharmacological techniques to investigate the molecular mechanisms underlying the inflammatory response of human neutrophils, with the aim of identifying potential therapeutic targets for diseases associated with neutrophils. Dr. Hwang's group has published more than 500 research papers and holds 40 patents.

Abdulaziz is a Ph.D. student at Kyungpook National University, Republic of Korea. He is supervised by Professor Sang-Hyun Kim, Department of Biomedical Science. His research focuses on the immunological mechanisms underlying inflammatory skin diseases, including atopic dermatitis, with an emphasis on translational approaches that bridge basic science and therapeutic development. His work aims to contribute to high-impact research in immunology and dermatological science.

Dr. Rajiv Jash is a pharmacologist and academician with over 17 years of experience in teaching and research in the field of pharmacy. He completed his B. Pharmacy (2002–2006) and M. Pharmacy in Pharmacology (2008–2010) from Biju Patnaik University of Technology, Odisha, followed by a Ph.D. in Pharmacology (2011–2016) from Singhania University, Rajasthan, where his doctoral work focused on the antipsychotic activity of selected medicinal plants. A GPAT-qualified candidate (AIR 1533, 2011), he has built a strong research profile in neuropharmacology, cardiovascular pharmacology, and immunology, with 25 research publications in reputed journals, 2 published patents, and several national and international conference presentations, including a first prize for poster presentation in 2013. Dr. Jash possesses extensive hands-on expertise in experimental pharmacology, histopathology, immunohistochemistry, and animal ethics administration. He currently serves as Associate Professor at Sanaka Educational Trust’s Bengal College of Pharmaceutical Technology, Durgapur, where he is also Member Secretary of the Institutional Animal Ethics Committee (IAEC) and CPCSEA Link Nominee for a neighbouring medical college institution. Throughout his career, he has taught pharmacology to diverse student groups including B.Pharm, BDS, B.Optom, BPT, and B.Sc. Nursing across institutions in Andhra Pradesh and West Bengal, and has significantly contributed to academic administration, GPAT coaching, and accreditation processes (NAAC/NBA).A potential reviewer for many scientific journals of Springer,Elsevier,Bentham Science,Wiley and Frontiers publication. Passionate about bridging traditional medicine with modern pharmacological research, Dr. Jash continues to explore phytomolecules for Neurological, Nephrological Cardiovascular, and Immunological disorders while mentoring the next generation of pharmacy professionals in India.Currently he is working exclusively on IgA nephropathy with his team at a research lab set up in his department.

2007-2010 Ph.D., Department of Anatomy and Tumor Immunity, Seoul National University College of Medicine, Seoul, Korea - Specialization: Oncology - Thesis title: “Foxp3 Expression Is Regulated in p53-Dependent Manner in Human Breast Cancer Cell lines” - Advisor: Dr. Wang Jae Lee 2010-2014 Postdoctoral Fellow, Center for Stem Cell Biology and Regenerative Medicine, Tsinghua University, Beijing, China 2016-present Postdoctoral Fellow, Micro Fluidics Labs, Asan Medical Center, Seoul, Korea

Yolanda Dyah Kartika is a lecturer and researcher at Universitas Gadjah Mada Indonesia. Her research focuses on breast cancer metastasis, with particular emphasis on therapeutic evaluation. This work aims to identify candidate therapeutic strategies and to predict treatment responses in breast cancer brain metastases using an ex vivo explant platform, thereby contributing to translational research while adhering to the 3R principles in animal experimentation.

Kushal Paneliya is a Bachelor of Health and Medical Sciences graduate from the University of Adelaide who works in clinical drug development. Kushal is an experienced Clinical Research Coordinator at Fusion Clinical Research in Adelaide, specializing in novel phase 2 proof of concept studies and large multi-center phase 3 clinical trials. He has ongoing academic interests in innovative clinical pharmacology approaches to accelerate drug development, and is a member of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and the American College of Clinical Pharmacology (ACCP).”

Namyi Gu, MD, PhD, is a professor in the Department of Clinical Pharmacology and Therapeutics at Dongguk University College of Medicine and Dongguk University Ilsan Hospital in South Korea. She received her medical degree from Seoul National University College of Medicine and completed her clinical pharmacology residency at Seoul National University Hospital, followed by fellowship training in clinical pharmacology at Asan Medical Center. Dr. Gu’s research focuses on pharmacokinetics and pharmacodynamics, drug–drug interactions, decentralized clinical trial (DCT) methodologies, herbal–synthetic drug interaction studies, and therapeutic drug monitoring. She is particularly interested in applying digital and decentralized research approaches to improve data integrity and participant experience. She is actively involved in national research projects on decentralized clinical trials and herbal–synthetic drug interactions, contributing to the modernization of clinical research infrastructures in Korea.

Dr. Qingyu Yao earned his Ph.D. in 2021 from School of Pharmaceutical Sciences, Peking University, specializing in PK/PD modelling with a focus on anticancer drugs. He subsequently conducted postdoctoral research in the Department of Immunology, Peking University, and then joined the Clinical Trial Center at Peking University First Hospital. Currently, he is primarily engaged in model-informed drug development (MiDD) and model-informed precision dosing (MiPD). Dr. Yao is a committee member of the Pharmacometric Committee of the Chinese Pharmacological Society. He has been the principal investigator of research projects, including one funded by the National Natural Science Foundation of China. Additionally, he has been deeply involved in the model-informed research for over ten innovative drug clinical trials, supporting dose selection across different phases of clinical development. His research has been published in journals such as Toxicology and Applied Pharmacology, Journal of Pharmaceutical Sciences and CPT Pharmacometrics & Systems Pharmacology.

Dr. Andrea Abate, PharmD, PhD, is a Hospital Pharmacist at the Clinical Trial Center of ASST Spedali Civili di Brescia and a postdoctoral researcher in the Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Italy. He completed a PhD in Precision Medicine at the University of Brescia and undertook international research training as a visiting PhD student at the University Hospital Zurich and the University of Birmingham. Dr. Abate also completed residency training in Clinical Pharmacology and Toxicology. His scientific activity focuses on oncological pharmacology, with particular expertise in adrenocortical carcinoma. He is the author or co-author of 30 peer-reviewed publications and has presented extensively at national and international conferences. Dr. Abate has received multiple awards for excellence in pharmacological research, including international research grants and best oral presentation awards.

Dr. Nurgul Ablakimova, MD, PhD, is an Assistant Professor in the Department of Pharmacology and Clinical Pharmacology at West Kazakhstan Marat Ospanov Medical University and serves as a Clinical Pharmacologist and Head of the Department of Hospital Pharmacy at the Regional Perinatal Center. Her primary research interests include antimicrobial resistance, antimicrobial stewardship, rational antibiotic therapy, and clinical pharmacology approaches in internal diseases. She is a medical doctor and a clinical pharmacologist of the 2nd qualification category with six years of combined clinical and teaching experience. Dr. Ablakimova actively contributes to intramural research projects and grant-funded studies supported by the Ministry of Science and Higher Education of Kazakhstan, helping to develop targeted educational and clinical interventions. She has authored original research articles, reviews, systematic reviews, and meta-analyses in peer-reviewed international journals and holds an h-index of 4. She is a member of the Association of Clinical Pharmacologists and Pharmacists of Kazakhstan and EACPT, and has participated in major scientific events, including WCP 2023 and EACPT 2024.

Gaziza Smagulova, MD, PhD, is a Professor and Head of the Department of Pharmacology and Clinical Pharmacology at West Kazakhstan Marat Ospanov Medical University. With 30 years of combined clinical and teaching experience, she is a medical doctor and clinical pharmacologist specializing in clinical pharmacology approaches in internal diseases, pharmacogenetics, antimicrobial resistance, antimicrobial stewardship, and rational antibiotic therapy. Dr Smagulova actively participates in both intramural research projects and grant-funded studies supported by the Ministry of Science and Higher Education of Kazakhstan and the Ministry of Health, contributing to the development of targeted educational and clinical interventions. She has co-authored original research articles and review papers, including systematic reviews and meta-analyses, published in peer-reviewed international journals indexed in Scopus and Web of Science, and has an h-index of 4. A member of the Association of Clinical Pharmacologists and Pharmacists of Kazakhstan and the European Association for Clinical Pharmacology and Therapeutics (EACPT), she is committed to evidence-based practice and antibiotic stewardship. She has participated in major scientific events, including EACPT 2025, and has received institutional and ministerial recognition for her contributions.

Dr. Osama H. Abusara is an Associate Professor of Pharmacology at the Department of Pharmacy at Al-Zaytoonah University of Jordan (ZUJ), Jordan. He has been working at ZUJ since 2017. Dr. Abusara obtained his Ph.D. degree in Pharmacy and Pharmaceutical Sciences from the University of Manchester, UK, in 2017 and his B.Sc. degree in Pharmacy from the University of Jordan, Jordan, in 2014. Dr. Abusara’s research interests include investigating novel compounds for cancer treatments, repurposing existing drugs for cancer treatment, molecular cancer, and peptide synthesis. He also collaborates with researchers of different pharmaceutical fields. Dr. Abusara has authored and co-authored more than 30 published papers in leading scientific journals. Dr. Abusara is a member of the Jordanian Pharmacists Association since 2014.

Elsa Alfiyanti is a Master’s student in Biomedical Sciences at the Faculty of Medicine, Universitas Andalas, Indonesia. She earned her Bachelor’s degree in Biology from the Faculty of Mathematics and Natural Sciences (FMIPA), Universitas Negeri Padang. From 2020 to 2022, she served as a laboratory analyst in COVID-19 diagnostics, supporting RT-PCR workflows, sample processing, and quality control in a high-throughput testing environment. She later joined a medical device company in West Sumatra as a Research and Development (R&D) specialist, focusing on the development and production of PCR reagents and panels for HPV, viral pneumonia/pneumonia, tuberculosis, and blood screening assays (HBV, HIV, HCV). Her work involves assay design support, reagent optimization, analytical performance evaluation, and documentation for routine implementation. Her current research focuses on recombinant enzyme development to strengthen local capacity and reduce reliance on imported molecular diagnostic reagents.

Professor Ju Yeon Ban serves at the College of Dentistry, Dankook University, Republic of Korea, where her research centers on periodontal disease mechanisms, stem cell-derived exosomes, nanoemulsion-based therapeutics, and genetic polymorphism–disease associations. She has led numerous nationally and privately funded research projects, contributed to interdisciplinary and international collaborations, and produced multiple publications and patents. Her current work includes exosome-mediated anti-inflammatory and periodontal regeneration strategies and multi-omics–driven target discovery using the UK Biobank. At this conference, she will speak on the anti-inflammatory and osteogenic roles of tonsil-derived stem cell exosomes.

Dr. Shouvik Choudhury is an Assistant Professor of Pharmacology at Burdwan Medical College, West Bengal, India. He earned his MBBS from Burdwan Medical College (2011) and an MD in Pharmacology from the Institute of Post Graduate Medical Education and Research, Kolkata (2018). Dr. Choudhury has over a decade of experience in teaching, research, and clinical pharmacology, having served as Senior Resident and Demonstrator prior to his current role. He has authored two widely used books on pharmacology and biostatistics, and published more than 40 articles in national and international indexed journals. His research has been presented at global forums, including the World Congress of Pharmacology in 2018 and 2023. Dr. Choudhury also serves as Deputy Coordinator of the Pharmacovigilance Committee at Burdwan Medical College, contributing to advancements in safe and effective medication use.

Camelia Dascălu is a Clinical Pharmacology Specialist and PhD candidate at the “Grigore T. Popa” University of Medicine and Pharmacy in Iași, Romania, and a research associate at the Advanced Center for Research and Development in Experimental Medicine (CEMEX). Her work focuses on translational pharmacology, bridging preclinical and clinical research, with particular emphasis on research methodology and regulatory aspects in biomedical studies. She is involved in multidisciplinary projects investigating the role of cannabinoids in oncology. Her experience includes clinical trial documentation, pharmacovigilance activities, study protocol development, and coordination of research teams across clinical and experimental settings.

Yingyi DENG is a PhD candidate in the School of Biomedical Science at the Chinese University of Hong Kong (CUHK). Her doctoral research focuses on uterine electrophysiology. Her research interests include studying uterine slow waves by using microelectrode array (MEA) techniques, aiming to extract features of uterine electrophysiological data for potential drug screening purposes.

I am a clinical pharmacologist and consultant physician with a primary focus on infectious diseases pharmacotherapy, antimicrobial stewardship, critical care pharmacology and herbal medicine. I am actively involved in intensive care unit (ICU) clinical practice, with particular expertise in pharmacokinetic–pharmacodynamic (PK/PD) optimization of anti-infective agents and therapeutic drug monitoring. My research interests include antimicrobial resistance (AMR), precision dosing strategies, and the integration of herbal medicine into evidence-based clinical pharmacology. I have also conducted and supervised studies on metabolic disorders, especially type 2 diabetes mellitus, focusing on insulin resistance mechanisms, DPP-4 inhibition, GLUT4 translocation, and the molecular effects of phytochemical compounds such as curcumin, green tea catechins, and cinnamon polyphenols. I am involved in academic teaching and research development, including initiatives in genomics, clinical pharmacology, and translational medicine. I am committed to advancing rational pharmacotherapy and bridging experimental research with clinical application to improve patient outcomes.

Dr. Pratibha Gaur is an early–mid career researcher with extensive postdoctoral experience in host–pathogen interactions and immunology. Her doctoral research at the International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, under the supervision of Dr. Sunil Lal, focused on Influenza A virus pathogenicity, in collaboration with the Influenza Division, CDC, Atlanta, USA. She pursued international postdoctoral research, training at the Helmholtz Centre for Infection Research, Germany, with Prof. Dagmar Wirth on obesity-driven immune dysregulation in hepatic and influenza-infected mouse models, and later at The Hebrew University of Jerusalem, Israel, with Prof. Francesca Levi-Schaffer, investigating mast cell and eosinophil functions in fungal infection and allergy. Currently, her research focuses on innate–adaptive immune crosstalk, allergic inflammation, and disease mouse models. She has received several prestigious national and international awards.

Haoyi Han is a PhD student at the Victor Chang Cardiac Research Institute, developing mathematical models to predict drug‑induced Torsades de Pointes and improve cardiac safety assessment during pharmaceutical development. She is a member of the Hill Group (Computational Cardiology Lab) and is supervised by A/Prof Adam Hill, Dr Stewart Heitmann, and Prof Jamie Vandenberg. Haoyi completed her undergraduate studies at UNSW Sydney, where she graduated with First‑Class Honours. She also serves as an academic tutor in pharmacology at UNSW and volunteers with the UNSW Postgraduate Council Research Department.

Sungpil Han, M.D., Ph.D., is an Assistant Professor in the Department of Pharmacology at the Catholic University of Korea, College of Medicine. Combining clinical expertise with advanced pharmaceutical research, he also serves as a Director and Program Manager at AIMS BioScience, where he bridges the gap between academic innovation and drug development strategy. Dr. Han is a specialist in pharmacometrics, with extensive experience in pharmacokinetic and pharmacodynamic (PK/PD) modeling and simulation. His current research focuses on the cutting-edge application of Microphysiological Systems (MPS) to predict human pharmacokinetics. By integrating ADME (Absorption, Distribution, Metabolism, and Excretion) aspects and Drug-Drug Interaction (DDI) evaluations, his work aims to develop robust alternatives to animal testing. An active contributor to the global regulatory science community, Dr. Han is dedicated to advancing pharmacology education and fostering international collaborations to streamline the transition from preclinical research to clinical success.

Yuta Amagasa is a PhD candidate in the Department of Clinical Pharmacology and Therapeutics at Gunma University. His research focuses on the molecular mechanisms of lenvatinib resistance in hepatocellular carcinoma, with particular interest in early-phase pathways mediated by c-SRC. He uses RNA sequencing, pathway analysis, and functional assays to study stepwise resistance acquisition and explore potential therapeutic targets. His wider interests include oncology pharmacology and resistance-overcoming strategies.

Zhenyan Bo is currently a researcher at the Department of Pharmacy, West China Second University Hospital, Sichuan University. She obtained his Master's degree from Sichuan University in 2019. Her research focuses on evidence-based pharmacy, employing methodologies such as evidence-based medicine, pharmacoepidemiology, and pharmacokinetics to explore rational drug use in children. The study submitted for this congress provided a comprehensive review of the pharmacokinetics of rituximab and its influencing factors, aiming to provide evidence-based evidence for the rational clinical use of rituximab in pediatric populations.

Dr Phurit Bovornchutichai is a physician-engineer with interdisciplinary training spanning nanoengineering, healthcare innovation and clinical medicine. He earned his Bachelor of Engineering in Nanoengineering from Chulalongkorn University, Thailand, followed by a Doctor of Philosophy (DPhil) in Healthcare Innovation from the University of Oxford, United Kingdom. He subsequently completed his Doctor of Medicine (MD) degree at Ramathibodi Hospital, Mahidol University, Thailand. Dr Phurit began his academic career in translational biomedical research, with a focus on drug delivery systems for cancer therapeutics and tissue engineering, particularly the development and application of co-culture cancer organoid models for studying tumour microenvironments and therapeutic responses. In recent years, Dr Phurit has consolidated his interdisciplinary expertise and shifted his research focus toward the integration of engineering, medicine, and management sciences to better understand patterns within healthcare systems and health professions education. His work aims to optimise clinical practice, educational outcomes and learner well-being through data-driven and technology-enabled approaches. His current research and development projects include: • Identification of potential drug-drug interactions using electronic database predictions, with validation against real-world clinical practice data • Comparative analysis of curricula and research projects between medical and pharmacy students to inform interprofessional education strategies • Development of human-artificial intelligence interaction systems to enhance clinical reasoning, decision-making skills and self-efficacy among healthcare students • Design and optimisation of a national peer support network to promote mental health and psychological well-being among healthcare students

Ye Chen, a Master's student in Clinical Pharmacy at Fujian Medical University.

Dr. Lkhagvajav Galbadrakh, MSc, is a teacher in the Department of General Sciences at Etugen Medical University, Ulaanbaatar, Mongolia. I am an early-career researcher from Mongolia, focusing on critical challenges in antibiotic use and antimicrobial resistance. Over the past two years, my work has concentrated on the pharmacokinetics of vancomycin and the mechanisms of resistance as part of a project evaluating its clinical utilization.

Aeri Ha is a Master’s student in the College of Pharmacy at Keimyung University (Daegu, Republic of Korea). Research focuses on pharmacokinetics and drug–drug interactions in the context of polysubstance exposure. Current work investigates neurobehavioral and pharmacokinetic interactions between methamphetamine and ketamine using animal models and LC–MS/MS-based bioanalysis. This study aims to elucidate the effects of combined drug exposure on systemic metabolism and identify the regulatory mechanisms underlying behavioral responses, thereby enhancing understanding of dose-dependent drug interactions during polysubstance use.

Jan Hlaváč, MD, is an early-career clinical pharmacologist and a second-year PhD student in the Pharmacology and Toxicology programme at the First Faculty of Medicine, Charles University, in Prague, Czech Republic. His research covers links between experimental pharmacology and clinical practice in various areas of pharmacodynamics within neurological and cardiovascular pharmacology. He also focuses on clinical and preclinical pharmacokinetics.

Ryuichiro Hosoya, PhD, is an Associate Professor in the Department of Clinical Pharmacy at Shonan Medical University. He worked as a hospital pharmacist for 15 years before earning a PhD in Pharmaceutical Sciences from the Graduate School of Meiji Pharmaceutical University. His research focuses on drug safety and the analysis of adverse drug events, including the development of predictive models of drug–receptor interactions using large-scale public　databases to elucidate adverse event mechanisms and enhance clinical risk assessment. He is also actively involved in emergency and disaster medicine pharmacy. Drawing on his experience as a disaster relief pharmacist, his work addresses medication supply systems during disasters and the roles of pharmacists in medical relief teams, with the aim of promoting safe medication practices and strengthening pharmacist preparedness for emergency situations. Research Interests -Drug safety and adverse event database analysis -Signal detection of adverse events using large-scale databases -Predictive modeling of drug–receptor interactions using BindingDB -Emergency and disaster medicine pharmacy -Roles of pharmacists in medical relief and disaster response

Dymphy Huntjens brings over 20 years of international experience in the pharmaceutical industry, specializing in pre-clinical and clinical quantitative drug development. She holds a PhD in Pharmacometrics from Leiden University in the Netherlands, where she also studied Bio-Pharmaceutical Sciences. Dymphy began her career as a clinical pharmacometrician at Grünenthal in Aachen, Germany. Before joining Priothera, she served as Scientific Director at Johnson & Johnson. As a global clinical pharmacology and pharmacometrics lead, Dymphy has overseen projects spanning both early and late stages of development. She has designed, executed, and analyzed innovative clinical development plans and studies. Her expertise spans a range of therapeutic areas, including infectious diseases, neurosciences, and oncology. Throughout her career, Dymphy has played a pivotal role in advancing drugs from the pre-clinical stage to first-in-human trials, through proof of concept, and ultimately to successful regulatory filings.

Haijing zhang Professor of Institute of Materia Medica, Chinese Academy of Medical Sciences Major research direction: Anti inflammatory and immunopharmacology

Prof. Jeong Ah Kim is currently working in College of Pharmcy, Kyungpook National University, Daegu, South Korea. She mainly interests in the Pharmacological Evaluation of Natural Products, Development and Standardization of Oriental Medicines, Development of New Drugs, Botanical Dietary Supplements and Functional Cosmetics from Natural Sources.

Dr. Hu graduated from China Pharmaceutical University in 2012. After graduation, she joined the Department of Pharmacy in a hospital, engaging in clinical pharmacy work. Her research directions are Therapeutic Drug Monitoring (TDM) and personalized medicine. She has published over 30 SCI papers and has been granted funding for more than 10 research projects.

Gabsik Yang, PhD, is an Associate Professor in the Department of Korean Medicine at Gachon University. His research primarily focuses on molecular immunology and aging, specifically investigating the NLRP3 inflammasome and cellular senescence.

I am Yoonmi Lee, a Principal Researcher at the Korea Institute of Oriental Medicine. I conduct research to develop health functional foods or pharmaceuticals using natural extracts, focusing primarily on gastrointestinal diseases (gastritis, reflux esophagitis, inflammatory bowel disease) and inflammation-related conditions such as arthritis and periodontitis.

Professor Abdulgafar O. Jimoh is a distinguished clinical pharmacologist and Provost of the College of Health Sciences at Usmanu Danfodiyo University, Sokoto, Nigeria. With an MBBS and PhD in Pharmacology, he brings extensive expertise in clinical and experimental pharmacology, drug use evaluation, pharmacokinetics, complementary and alternative medicine, and pharmacoepidemiology. As a seasoned academic and researcher, Professor Jimoh has made significant contributions to pharmacological research and medical education in Nigeria. His work focuses on rational drug use, clinical audits, and improving therapeutic outcomes in resource-limited settings. He has published numerous peer-reviewed articles and actively mentors postgraduate students while leading initiatives to strengthen pharmacology training and research capacity. Passionate about bridging basic pharmacology with clinical practice, Professor Jimoh is committed to advancing evidence-based therapeutics and global health. At WCP2026, he will share insights from his latest research on CXCL13 and IFN-γ as predictors of immune response to hepatitis B vaccine,

Toni Michael is a Clinical Pharmacology PhD candidate from the School of Pharmacy at the University of Sydney (supervised by A/Prof. Sophie Stocker). Her research is on understanding the pharmacodynamic and pharmacokinetic properties of commonly prescribed fertility mediations to inform optimal use of medications in practice.

Robin Lu is a Bachelor of Pharmacy and Management Honours student at the University of Sydney, supervised by Associate Professor Sophie Stocker. His Honours project focuses on implementing model-based clinical decision support tools to optimise ovarian response to gonadotropins administered for controlled ovarian hyperstimulation.

Xiangchang Zeng earned his Ph.D. in Pharmacology from Central South University and is currently a postdoctoral fellow at Shenzhen Third People's Hospital (The Second Affiliated Hospital of Southern University of Science and Technology). His research focuses on the pharmacology and toxicology of traditional Chinese medicine and natural products, as well as the pathogenesis of hepatocellular carcinoma, with the goal of identifying novel therapeutic targets and effective treatment strategies. He has published over 20 papers and been granted 3 patents.

Katie Burns is a Senior Lecturer (Above the Bar) in Pharmacology and Clinical Pharmacology at Waipapa Taumata Rau, University of Auckland. Her research investigates the molecular basis of drug disposition and how transporters and metabolic enzymes shape the effectiveness and safety of medicines, with a focus on therapeutic drug monitoring and pharmacodynamic biomarkers developed in partnership with clinicians. She has led and contributed to studies spanning oncology, psychiatry and autoimmune disease, including systemic lupus erythematosus, and has expertise in drug and metabolite bioanalysis, cell culture, bioassays, and molecular biology.

Noha Kamel is a third-year international PhD student and a casual academic at the University of Sydney’s School of Pharmacy. She holds international tuition and stipend scholarships from the University of Sydney, and is supervised by A/Prof. Sophie Stocker, A/Prof. Ronald Castelino, A/Prof. Daniel Wright, and Dr. Stephen Hughes. Her research focuses on gout management in patients with end-stage chronic kidney disease. She published a scoping review on allopurinol PK and PD in dialysis patients and a retrospective clinical chart review of allopurinol dosing practices and serum urate concentrations in a cohort of gout patients receiving dialysis. She is presenting on her PKPD proof of concept simulation study to explore the impact of gradual allopurinol deprescribing in gout patients receiving haemodialysis on serum urate concentrations.